Advanced Solid Tumor Clinical Trials

122 studies are recruiting for advanced solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arizona Cancer Center, Tucson, Arizona

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

2. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

   The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   30 in total

   Run by

   Coherus Oncology, Inc.

   See if you can join NCT06657144 on ClinicalTrials.gov

3. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

   The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   21 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06997029 on ClinicalTrials.gov

4. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

5. A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California

   Locations

   52 in total

   Run by

   BeOne Medicines

   See if you can join NCT06625593 on ClinicalTrials.gov

6. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

7. SNV1521 in Participants With Advanced Solid Tumors

   This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also invest…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

   Locations

   25 in total

   Run by

   Synnovation Therapeutics, Inc.

   See if you can join NCT06220864 on ClinicalTrials.gov

8. Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

   This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose e…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California at Davis Cancer Center, Sacramento, California

   Locations

   8 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06352359 on ClinicalTrials.gov

9. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

   This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #5, San Francisco, California

   Locations

   11 in total

   Run by

   Exelixis

   See if you can join NCT06952010 on ClinicalTrials.gov

10. XTX301 in Patients With Advanced Solid Tumors

    This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Davis Comprehensive Cancer Center, Sacramento, California

    Locations

    12 in total

    Run by

    Xilio Development, Inc.

    See if you can join NCT05684965 on ClinicalTrials.gov

11. A Study of YL201 in Patients With Advanced Solid Tumors

    This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    002, Fair Oaks, California

    Locations

    45 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT05434234 on ClinicalTrials.gov

12. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

    This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale New Haven Hospital, New Haven, Connecticut

    Locations

    17 in total

    Run by

    SillaJen, Inc.

    See if you can join NCT05768932 on ClinicalTrials.gov

13. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

    This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    The University of Arizona Cancer Center, Tucson, Arizona

    Locations

    57 in total

    Run by

    Eikon Therapeutics

    See if you can join NCT06253130 on ClinicalTrials.gov

14. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

    The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07638371 on ClinicalTrials.gov

15. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

    A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Scottsdale, Arizona

    Locations

    10 in total

    Run by

    Plexium, Inc.

    See if you can join NCT07284186 on ClinicalTrials.gov

16. Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

    This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461,…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Los Angeles, Santa Monica, California

    Locations

    8 in total

    Run by

    Senhwa Biosciences, Inc.

    See if you can join NCT04890613 on ClinicalTrials.gov

17. Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

    This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Run by

    Lei Zheng

    See if you can join NCT07086768 on ClinicalTrials.gov

18. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at HealthONE, Denver, Colorado

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

19. Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

    This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therap…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Robert Bok, MD, PhD

    See if you can join NCT05599048 on ClinicalTrials.gov

20. A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

    This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institiute, Scottsdale, Arizona

    Locations

    8 in total

    Run by

    Peel Therapeutics Inc

    See if you can join NCT05329103 on ClinicalTrials.gov

21. Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

    This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable si…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT06302621 on ClinicalTrials.gov

22. Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

    The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are t…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Mountain Region, West Valley City, Utah

    Run by

    Lantern Pharma Inc.

    See if you can join NCT06132503 on ClinicalTrials.gov

23. Study in Advanced Solid Tumor Patients

    The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumo…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute 335 24th Avenue North, Suite 400, Nashville, Tennessee

    Locations

    11 in total

    Run by

    Callio Therapeutics

    See if you can join NCT07300943 on ClinicalTrials.gov

24. GTB-5550 in Advanced Solid Tumors

    This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07541573 on ClinicalTrials.gov

25. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arkansas Medical School, Little Rock, Arkansas

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov